Large B-cell Lymphoma

Oncology
7
Pipeline Programs
6
Companies
8
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
Cell Therapy
240%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
3 programs
1
1
Telemedicine VisitPhase 41 trial
Comprehensive Ablative Bridging IrradiationPhase 21 trial
Axicabtagene CiloleucelN/ACell Therapy1 trial
Active Trials
NCT05776160Available
NCT06104592Recruiting27Est. Dec 2026
NCT05108805Completed25Est. Dec 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD0486Phase 31 trial
Active Trials
NCT07215585Recruiting420Est. Jul 2033
Swedish Orphan Biovitrum
1 program
1
EmapalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06550141RecruitingEst. Aug 2027
ADC Therapeutics
ADC TherapeuticsNJ - New Providence
1 program
1
EpcoritamabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06919939RecruitingEst. Jan 2031
Allogene Therapeutics
Allogene TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
cemacabtagene ansegedleucelPhase 2Cell Therapy1 trial
Active Trials
NCT06500273RecruitingEst. Aug 2031
Genentech
GenentechCA - Oceanside
1 program
1
MosunetuzumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05464329Active Not Recruiting24Est. Oct 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Gilead SciencesTelemedicine Visit
AstraZenecaAZD0486
ADC TherapeuticsEpcoritamab
Swedish Orphan BiovitrumEmapalumab
Allogene Therapeuticscemacabtagene ansegedleucel
Gilead SciencesComprehensive Ablative Bridging Irradiation
GenentechMosunetuzumab

Clinical Trials (8)

Total enrollment: 496 patients across 8 trials

NCT05108805Gilead SciencesTelemedicine Visit

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Start: Dec 2021Est. completion: Dec 202325 patients
Phase 4Completed
NCT07215585AstraZenecaAZD0486

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Start: Nov 2025Est. completion: Jul 2033420 patients
Phase 3Recruiting
NCT06919939ADC TherapeuticsEpcoritamab

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

Start: Jan 2026Est. completion: Jan 2031
Phase 2Recruiting
NCT06550141Swedish Orphan BiovitrumEmapalumab

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Start: Sep 2024Est. completion: Aug 2027
Phase 2Recruiting
NCT06500273Allogene Therapeuticscemacabtagene ansegedleucel

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Start: Jun 2024Est. completion: Aug 2031
Phase 2Recruiting
NCT06104592Gilead SciencesComprehensive Ablative Bridging Irradiation

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Start: Nov 2023Est. completion: Dec 202627 patients
Phase 2Recruiting
NCT05464329GenentechMosunetuzumab

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Start: Jan 2023Est. completion: Oct 202924 patients
Phase 1Active Not Recruiting
NCT05776160Gilead SciencesAxicabtagene Ciloleucel

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

N/AAvailable

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
5h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 496 patients
Monoclonal Antibody is the dominant modality (60% of programs)
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)